Kimberly-Clark Announces $48.7 Billion Acquisition of Kenvue

On November 3, 2025, Kimberly-Clark Corporation unveiled plans to acquire Kenvue, the maker of Tylenol, in a cash-and-stock transaction valued at approximately $48.7 billion. This strategic move aims to consolidate a vast array of consumer health brands under one corporate umbrella.

Details of the Acquisition

Under the terms of the agreement, Kenvue shareholders will receive $21.01 per share, representing a 46.2% premium over the company’s last closing price. Post-acquisition, Kimberly-Clark shareholders will own about 54% of the combined entity, while Kenvue shareholders will hold the remaining 46%. The merger is projected to generate annual revenues of approximately $32 billion.

Strategic Implications

The acquisition brings together a diverse portfolio of well-known brands, including Kenvue’s Tylenol, Listerine, and Band-Aid, alongside Kimberly-Clark’s Huggies, Kleenex, and Cottonelle. This consolidation is expected to enhance market reach and operational efficiencies. Kimberly-Clark anticipates achieving $2.1 billion in annual cost savings and improved brand performance following the merger, which is slated to close in the second half of 2026.

Market Reactions and Financial Outlook

Following the announcement, Kenvue’s shares rose approximately 20% in premarket trading, while Kimberly-Clark’s shares declined nearly 15%. Despite recent challenges, including a 3.5% decline in Kenvue’s third-quarter net sales to $3.76 billion, the company reaffirmed its 2025 profit outlook of $1.00–$1.05 per share. Kimberly-Clark, known for its resilient performance, reported third-quarter net sales of $4.15 billion, surpassing analysts’ expectations.

Leadership and Future Prospects

Kimberly-Clark’s CEO, Mike Hsu, will lead the combined company. The merger is expected to create a consumer health powerhouse, leveraging the strengths of both organizations to drive innovation and growth in the sector.